LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Ovid therapeutics Inc

Suletud

SektorTervishoid

1.25 5.04

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.13

Max

1.29

Põhinäitajad

By Trading Economics

Sissetulek

5.6M

-4.7M

Müük

6.1M

6.3M

Kasumimarginaal

-74.681

Töötajad

23

EBITDA

7.3M

-5.1M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+139.34% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

10. nov 2025

Turustatistika

By TradingEconomics

Turukapital

42M

81M

Eelmine avamishind

-3.79

Eelmine sulgemishind

1.25

Uudiste sentiment

By Acuity

43%

57%

151 / 372 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Ovid therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. aug 2025, 22:51 UTC

Tulu

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27. aug 2025, 23:57 UTC

Tulu

Trip.com Group 1H Rev $4.01B

27. aug 2025, 23:57 UTC

Tulu

Trip.com Group 1H Adj EPS $1.84

27. aug 2025, 23:57 UTC

Tulu

Trip.com Group 1H EPS $1.82

27. aug 2025, 23:50 UTC

Market Talk

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27. aug 2025, 23:39 UTC

Tulu

Correction to Nvidia Earnings Article -- WSJ

27. aug 2025, 22:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. aug 2025, 22:59 UTC

Market Talk

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27. aug 2025, 22:58 UTC

Tulu

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27. aug 2025, 22:57 UTC

Tulu

South32 FY Free Cash Flow $192 Million

27. aug 2025, 22:56 UTC

Tulu

South32 FY Total Capital Expenditure $1.35 Billion

27. aug 2025, 22:56 UTC

Tulu

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27. aug 2025, 22:55 UTC

Tulu

South32 Net Cash $123 Million at June 30

27. aug 2025, 22:54 UTC

Tulu

South32: Focused on Maintaining Strong Operating Momentum

27. aug 2025, 22:53 UTC

Tulu

South32: $144 Million Remains to be Returned to Shareholders Under Program

27. aug 2025, 22:53 UTC

Tulu

South32 Extends Capital Management Program for 12 Months

27. aug 2025, 22:52 UTC

Tulu

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27. aug 2025, 22:51 UTC

Tulu

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27. aug 2025, 22:51 UTC

Tulu

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27. aug 2025, 22:50 UTC

Tulu

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27. aug 2025, 22:50 UTC

Tulu

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27. aug 2025, 22:45 UTC

Tulu

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27. aug 2025, 22:44 UTC

Tulu

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27. aug 2025, 22:44 UTC

Tulu

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27. aug 2025, 22:43 UTC

Tulu

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27. aug 2025, 22:43 UTC

Tulu

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27. aug 2025, 22:42 UTC

Tulu

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27. aug 2025, 22:42 UTC

Tulu

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27. aug 2025, 22:40 UTC

Tulu

Sandfire Resources Net Debt $123 Million at June 30

27. aug 2025, 22:40 UTC

Tulu

Sandfire Resources FY Underlying Ebitda $527.7 Million

Võrdlus sarnastega

Hinnamuutus

Ovid therapeutics Inc Prognoos

Hinnasiht

By TipRanks

139.34% tõus

12 kuu keskmine prognoos

Keskmine 2.92 USD  139.34%

Kõrge 5.5 USD

Madal 0.5 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Ovid therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

7

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.275 / 0.33Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

151 / 372 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.